GLUBRAVA 15mg / 850mg film-coated tablets medication leaflet

A10BD05 pioglitazone + metformin • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs

The combination of pioglitazone and metformin is used in the treatment of type 2 diabetes to improve glycemic control. Pioglitazone works by increasing insulin sensitivity, while metformin reduces hepatic glucose production and improves glucose utilization by muscles.

The medication is taken orally, as directed by a doctor, usually once or twice daily with meals. It is important for patients to follow the treatment regimen and adopt a healthy lifestyle, including a balanced diet and regular exercise.

Patients should be aware of potential side effects, such as nausea, diarrhea, or weight gain. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, diarrhea, and weight gain. In rare cases, severe reactions such as lactic acidosis or liver failure may occur. Patients should be informed of these risks before use.

General data about GLUBRAVA 15mg / 850mg

Substance: pioglitazone + metformin

Date of last drug list: 01-07-2013

Commercial code: W51458007

Concentration: 15mg / 850mg

Pharmaceutical form: film-coated tablets

Quantity: 90

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Other substances similar to pioglitazone + metformin